Fractyl's Revita faces its first randomized weight-maintenance test in Q3
REMAIN-1 Midpoint Cohort data due by September 30 will show whether a duodenal-lining procedure can hold weight loss after patients stop tirzepatide, a question with no approved answer yet.
Executive Summary
- Fractyl Health is heading toward the first randomized, sham-controlled readout testing whether a procedural therapy can preserve weight loss after patients stop a GLP-1 drug, a question no approved treatment currently answers.
- An earlier post-hoc look at the same cohort found the treatment effect grew with procedural dose and with how much weight a patient had already lost on the GLP-1 drug, giving the randomized data a specific, dose-response pattern to confirm rather than a blank slate.
- No other program is running a randomized trial of a procedural or device-based approach to post-GLP-1 weight maintenance, so the readout will land in a field defined mostly by GLP-1 drugs themselves rather than by a direct procedural rival.
- The trial's registry completion date sits months past the stated readout window, a reflection of interim-cohort reporting inside a longer-running pivotal program rather than a delay to the near-term data.
The catalyst
The readout comes from NCT06484114, a sham-controlled, randomized study enrolling adults with obesity who lost at least 15% of their body weight on tirzepatide and then discontinued it. Fractyl's Chief Executive Officer, Harith Rajagopalan, framed the addressable problem in a March 24, 2026 disclosure: roughly 30 million patients are projected to be on GLP-1 drugs by 2035, and most will face discontinuation and weight regain. The Midpoint Cohort's 1-year randomized data, expected in the stated July-to-September 2026 window, is the near-term test of that thesis, ahead of a separate Pivotal Cohort readout the company has guided to early Q4 2026. NCT06484114+1Evaluation of the Safety and Efficacy of Revita® DMR on Body Weight Maintenance in Subjects With Obesity Who Have Achieved at Least 15% Weight Loss on TirzepatideNCT06484114Fractyl Health Reports Fourth Quarter and Full Year 2025 Financial Results and Business UpdatesMar 24, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What the interim data showed
Fractyl reported post-hoc analyses of the same Midpoint Cohort at 6 months, based on 45 patients, showing a statistically significant correlation between the length of duodenal ablation and weight maintenance in the Revita arm (n=29, p=0.048). Among patients who had lost more weight on tirzepatide before randomization, the sham-adjusted treatment effect widened from 1 to 6 months, with a 70% reduction in weight regain relative to sham in that above-median subgroup (p=0.004). Rajagopalan described the pattern as a dose-response relationship, the kind more typically associated with drugs than with a one-time procedure. The randomized 1-year data due this quarter will show whether that pattern holds as follow-up extends and the analysis moves from post-hoc subgroups to the cohort's full 1-year comparison. FractylFractyl Health Reports Fourth Quarter and Full Year 2025 Financial Results and Business UpdatesMar 24, 2026
The trial's operational footing
The study is Active, not recruiting, with a target enrollment of 315 that has not changed since the trial's registration, a routine hold rather than a cut or an expansion. Its registered primary completion date moved from September 30, 2026 to February 15, 2027 as of a March 3, 2026 registry update, a five-month shift that reflects the trial's move from the Midpoint Cohort toward the longer Pivotal Cohort rather than a delay to the Q3 2026 interim data window. The trial has logged one status change to recruiting, one to active-not-recruiting, and this single completion-date change since it opened in 2024, a change pattern read as stable rather than volatile. NCT06484114Evaluation of the Safety and Efficacy of Revita® DMR on Body Weight Maintenance in Subjects With Obesity Who Have Achieved at Least 15% Weight Loss on TirzepatideNCT06484114
The competitive frame
No other program in the post-GLP-1 weight maintenance space is running a randomized procedural or device trial comparable to Revita; the closest activity in the field consists of GLP-1 and GLP-1-adjacent drug trials from Novo Nordisk and Eli Lilly, along with a behavioral-treatment study and a bariatric-surgery trial, none of which test a duodenal procedure against the discontinuation-and-regain problem this trial targets. Revita's FDA Breakthrough Device designation for weight maintenance in patients who discontinue GLP-1 therapy, granted for this indication, signals the agency's view of unmet need in this specific population, not a predicted trial outcome. With no validated procedural or pharmacological standard for preventing regain after GLP-1 discontinuation, a result that reproduces the dose-dependent, sham-adjusted separation seen at 6 months, and shows it persisting or widening at 1 year, is the finding that would extend the interim signal into a resolvable readout.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.